45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
2,637
Insurances with rates
4
CPT / HCPCS codes
2,111
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J9228 | IPILIMUMAB 200 MG 40 ML [ECHA] | $172,169 | $103,301 | — | — | 6 |
| 988 | NONEXTENSIVE O.R. PROCEDURE UNRELATED TO PRINCIPAL DIAGNOSIS WITH CC | $156,383 | $93,830 | — | — | 6 |
| J2350 | OCRELIZUMAB 300MG10ML 30MGML 300 MG 10 ML [ECHA] | $97,500 | $58,500 | — | — | 6 |
| J9043 | CABAZITAXEL EA ONC 340EAB 60 MG 1 EA [ECHA] | $62,867 | $37,720 | — | — | 5 |
| J3055 | talquetamabEAtgvs 40 mgmL Sol[ECHA] | $62,160 | $37,296 | — | — | 4 |
| J9380 | TeclistamabEAcqyv 153 mg 1.7 mL Sol | $58,292 | $34,975 | — | — | 4 |
| J9119 | cemiplimab 350 mg7 mL Sol [ECHA] | $55,419 | $33,251 | — | — | 5 |
| J1932 | lanreotide 120 mg0.5 mL Sol | $53,356 | $32,014 | — | — | 5 |
| J9316 | hyaluronidasepertuzumabtrastuzumab 20000 unitsEA600 mgEA600 mg10 mL Sol[ECHA] | $50,826 | $30,496 | — | — | 5 |
| J9042 | brentuximab vedotin 50 mg Pow [ECHA] | $47,760 | $28,656 | — | — | 5 |
| J9144 | daratumumabEAhyaluronidase 1800 mgEA30000 units15 mL Sol[ECHA] | $45,444 | $27,266 | — | — | 5 |
| J9300 | GEMTUZUMAB OZOGAMICIN 5 MG 1 EA [ECHA] | $42,822 | $25,693 | — | — | 0 |
| 207 | RESPIRATORY SYSTEM DIAGNOSIS WITH VENTILATOR SUPPORT less than96 HOURS | $40,746 | $24,447 | — | — | 6 |
| 790 | EXTREME IMMATURITY OR RESPIRATORY DISTRESS SYNDROME NEONATE | $40,300 | $24,180 | — | — | 6 |
| J9223 | lurbinectedin 4 mg Pow [ECHA] | $39,798 | $23,879 | — | — | 5 |
| J9301 | obinutuzumab 25 mgmL Sol [ECHA] | $38,725 | $23,235 | — | — | 5 |
| J9299 | nivolumab 240 mg24 ml Sol [ECHA] | $37,758 | $22,655 | — | — | 5 |
| J2506 | PEGFILGRASTIM 6 MG 0.6 ML | $37,386 | $22,432 | — | — | 5 |
| 329 | MAJOR SMALL AND LARGE BOWEL PROCEDURES WITH MCC | $37,251 | $22,350 | — | — | 6 |
| J3380 | VEDOLIZUMAB 300 MG 1 EA [ECHA] | $36,585 | $21,951 | — | — | 5 |
| 728 | INFLAMMATION OF THE MALE REPRODUCTIVE SYSTEM WITHOUT MCC | $35,243 | $21,146 | — | — | 6 |
| J3101 | TENECTEPLASE 50 MG 1 EA [ECHA] | $35,171 | $21,103 | — | — | 15 |
| 853 | INFECTIOUS AND PARASITIC DISEASES WITH O.R. PROCEDURE WITH MCC | $30,743 | $18,446 | — | — | 6 |
| J9306 | PERTUZUMAB EA 420 MG 14 ML [ECHA] | $30,075 | $18,045 | — | — | 5 |
| 793 | FULL TERM NEONATE WITH MAJOR PROBLEMS | $28,540 | $17,124 | — | — | 6 |
| 791 | PREMATURITY WITH MAJOR PROBLEMS | $27,807 | $16,684 | — | — | 6 |
| J0717 | certolizumab 200 mgmL Kit[ECHA] | $27,782 | $16,669 | — | — | 5 |
| J1459 | IMMUNE GLOBULIN HUMAN PRIVIGEN 10% INTRAVENOUS 40 GM 400 ML [ECHA] | $26,640 | $15,984 | — | — | 5 |
| Q5115 | riTUXimab abbs 500 mg 50mL Sol [ECHA] | $25,367 | $15,220 | — | — | 5 |
| J9271 | PEMBROLIZUMAB EA 100 MG 4 ML [ECHA] | $25,341 | $15,204 | — | — | 5 |
| 673 | OTHER KIDNEY AND URINARY TRACT PROCEDURES WITH MCC | $25,182 | $15,109 | — | — | 6 |
| Q5108 | pegfilgrastimEAjmdb 6 mg0.6 mL | $25,050 | $15,030 | — | — | 5 |
| J2353 | OCTREOTIDE ACETATE 30 MG 1 EA [ECHA] | $24,431 | $14,659 | — | — | 10 |
| 335 | PERITONEAL ADHESIOLYSIS WITH MCC | $24,375 | $14,625 | — | — | 6 |
| J9177 | enfortumab vedotinEAejfv 30 mg Pow [ECHA] | $23,856 | $14,314 | — | — | 5 |
| 987 | NONEXTENSIVE O.R. PROCEDURE UNRELATED TO PRINCIPAL DIAGNOSIS WITH MCC | $23,072 | $13,843 | — | — | 6 |
| J1162 | DIGOXIN IMMUNE FAB OVINE 40 MG 1 EA [ECHA] | $21,834 | $13,100 | — | — | 5 |
| J0597 | C1 esterase inhibitor Berinert human 500 intl units Kit | $21,724 | $13,034 | — | — | 5 |
| Q5119 | riTUXimab pvvr 500 mg50ml Sol [ECHA] | $21,504 | $12,902 | — | — | 5 |
| 415 | CHOLECYSTECTOMY EXCEPT BY LAPAROSCOPE WITHOUT C.D.E. WITH CC | $21,323 | $12,794 | — | — | 6 |
| J1306 | Inclisiran 284 mg1.5 mL Sol | $20,240 | $12,144 | — | — | 5 |
| 817 | OTHER ANTEPARTUM DIAGNOSES WITH O.R. PROCEDURE WITH MCC | $19,396 | $11,637 | — | — | 6 |
| 240 | AMPUTATION FOR CIRCULATORY SYSTEM DISORDERS EXCEPT UPPER LIMB AND TOE WITH CC | $19,346 | $11,607 | — | — | 6 |
| J9207 | IXABEPILONE ONC 340EAB 45 MG 1 EA [ECHA] | $18,942 | $11,365 | — | — | 5 |
| 208 | RESPIRATORY SYSTEM DIAGNOSIS WITH VENTILATOR SUPPORT greater thanor equal to96 HOURS | $18,654 | $11,192 | — | — | 6 |
| 981 | EXTENSIVE O.R. PROCEDURE UNRELATED TO PRINCIPAL DIAGNOSIS WITH MCC | $18,194 | $10,916 | — | — | 6 |
| J9354 | ADOEATRASTUZUMAB EMTANSINE 100 MG 1 EA [ECHA] | $17,927 | $10,756 | — | — | 5 |
| 84154 | Free PSA | $17,867 | $10,720 | — | — | 6 |
| G0372 | 90375 Rabies immune globulin Igg | $17,867 | $10,720 | — | — | 1 |
| 982 | EXTENSIVE O.R. PROCEDURE UNRELATED TO PRINCIPAL DIAGNOSIS WITH CC | $17,223 | $10,334 | — | — | 6 |
Showing top 50 of 2,637 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.